Immucor, a healthcare products company based in Norcross, Georgia, announced that it would acquire Hologics’ Lifecodes division for $85 million. According to a press release by the company, the new acquisition could be worth up to $95 million if Hologic meets certain financial milestones. This is Immucor’s first acquisition since CEO William Hawkins (previously CEO of Medtronic) took office.
Lifecodes is the transplant diagnostics division of Hologics. In the press release, Immucor stated that Lifecodes is a “worldwide leader in transplantation diagnostics.” The company believes that the total market for transplantation diagnostics is worth an estimated $400 million and will continue to grow in the future. Hologic acquired Lifecodes in August of 2012 during the $4 billion acquisition of Gen-Probe, a molecular diagnostics company.
William Hawkins is CEO and president of Immucor. In prepared remarks, he said, "The Lifecodes business will extend our mission to organs and stem cells." He continued, "The clear market advantage here is that customers anywhere in the world will have a single source for proven diagnostics that has a core competency in antigen typing and antibody screening and identification."
Hawkins has served as CEO of Immucor since October of 2011. Immucor’s previous CEO was Joshua Levine. Levine now serves as CEO and president of Accuray, a radiosurgery technology company.
- Official MD&M East Brochure - Supplier Resource
- Design Tips for Rapid Injection Molding - Supplier Resource
- Smoothing the Path to Secure Smart Grids for Integrators - Supplier Resource
- Smoothing the Path to Secure Smart Grids for Manufacturers - Supplier Resource
- Point-of-care drug monitoring system - Supplier Resource
- The Four Myths of Time and Materials Estimates - Supplier Resource